Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid fail...
Leveraging Trump’s impending tariffs, pharma companies have called on Europe aga...
The US Food and Drug Administration (FDA) has granted approval for Neurelis’ dia...
BMS could soon face competition in the HCM space as Cytokinetics awaits a market...
One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the ...
At the ESCMID Global conference in Austria, the development of climate-informed ...
Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) f...
The FDA will require an additional Phase III trial for apraglutide, the company'...
Valneva has received marketing authorisation from the Brazilian Health Regulator...
Boehringer and Cue Biopharma have entered a strategic research partnership and l...
J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its prof...
The FDA has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab)...
Novartis plans new manufacturing sites and a second R&D hub as it shifts key ope...
Pluri has announced the issuance of a patent by the US Patent and Trademark Offi...
